Teduglutide (Gattex) for Fat Loss
FDA-approved GLP-2 analog that promotes intestinal mucosal growth and absorption, used for short bowel syndrome in patients dependent on parenteral support.
Why Teduglutide (Gattex) for fat loss?
According to PubMed, a population-PK and exposure-response analysis across 219 patients found teduglutide 0.05 mg/kg daily produced a maximum reduction in parenteral support of about 5.76 L/week, with an elimination half-life near 1.47 hours in short bowel syndrome (Marier JF et al., Clin Transl Sci 2021). It is FDA-approved (Gattex/Revestive) and well characterized by its label.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Teduglutide (Gattex) fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Increases intestinal villus height and crypt depth, improving absorption
- Reduces dependence on parenteral nutrition and IV fluids in short bowel syndrome
- Approved for both adult and pediatric short bowel syndrome
Reference dosing by bodyweight
Anchored to the most-cited research dose (5000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 3117–4217 mcg |
| 60–75 kg / 132–165 lb | 3825–5175 mcg |
| 75–90 kg / 165–198 lb | 4675–6325 mcg |
| 90–105 kg / 198–231 lb | 5525–7475 mcg |
| >105 kg / >231 lb | 6375–8625 mcg |
Side effects to weigh against fat loss benefit
- Abdominal pain
- Nausea
- Injection-site reactions
- Fluid overload
- Stoma-related complications
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.